Real Clinical Effectiveness of Molnupiravir Against 30-day
Mortality Among 74 541 SARS-CoV-2-Positive Patients: A
Nationwide Cohort Study From the Czech Republic

CSLog in Log in (EduId)

Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 ...

Přehled o publikaci

J 2024

Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic

PAVLÍK, Tomáš, Jiří JARKOVSKÝ, Ondřej ŠANCA, Martina KOZIAR VASAKOVA, Pavel DLOUHY et. al.

Basic information

Original name

Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic

Authors

PAVLÍK, Tomáš, Jiří JARKOVSKÝ, Ondřej ŠANCA, Martina KOZIAR VASAKOVA, Pavel DLOUHY, Vladimir CERNY, Petr ŠTOURAČ, Vlastimil VÁLEK and Ladislav DUŠEK

Edition

OPEN FORUM INFECTIOUS DISEASES, CARY, OXFORD UNIV PRESS INC, 2024, 2328-8957

Other information

Language

English

Type of outcome

Article in a journal

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Organization

Lékařská fakulta – Repository – Repository

DOI

http://dx.doi.org/10.1093/ofid/ofae685

UT WoS

001374759800001

EID Scopus

2-s2.0-85212131397

Keywords in English

30-day all-cause mortality; COVID-19; COVID-19-related mortality; molnupiravir; SARS-CoV-2 infection

Links

LX22NPO5101, research and development project.

Changed: 7/2/2025 00:50, RNDr. Daniel Jakubík

Abstract

V originále

lt; .001). The effect of molnupiravir was highly significant regardless of sex, Deyo-Charlson Comorbidity Index score, hospitalization status, COVID-19 vaccination status, and patients older than age 65 years. Conclusions. In this cohort study, early initiation of molnupiravir was associated with a significant reduction in 30-day all-cause and COVID-19-related mortality in adult SARS-CoV-2 positive patients.

Files attached

https://is.muni.cz/publication/2475062/Real_Clinical_Effectiveness_of_Molnupiravir_Against_30-day_Mortality_Among_74_541_SARS-CoV-2-Positive_Patients_A_Nationwide_Cohort_Study_From_the_Czech_Republic.pdf

Cite

PAVLÍK, Tomáš, Jiří JARKOVSKÝ, Ondřej ŠANCA, Martina KOZIAR VASAKOVA, Pavel DLOUHY, Vladimir CERNY, Petr ŠTOURAČ, Vlastimil VÁLEK and Ladislav DUŠEK. Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic. OPEN FORUM INFECTIOUS DISEASES. CARY: OXFORD UNIV PRESS INC, 2024, vol. 11, No 12, p. 1-10. ISSN 2328-8957. Available from: https://dx.doi.org/10.1093/ofid/ofae685.

@article{67808,
   author = {Pavlík, Tomáš and Jarkovský, Jiří and Šanca, Ondřej and Koziar Vasakova, Martina and Dlouhy, Pavel and Cerny, Vladimir and Štourač, Petr and Válek, Vlastimil and Dušek, Ladislav},
   article_location = {CARY},
   article_number = {12},
   doi = {http://dx.doi.org/10.1093/ofid/ofae685},
   keywords = {30-day all-cause mortality; COVID-19; COVID-19-related mortality; molnupiravir; SARS-CoV-2 infection},
   language = {eng},
   issn = {2328-8957},
   journal = {OPEN FORUM INFECTIOUS DISEASES},
   title = {Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic},
   url = {https://academic.oup.com/ofid/article/11/12/ofae685/7904736?login=true},
   volume = {11},
   year = {2024}
}

TY  - JOUR
ID  - 67808
AU  - Pavlík, Tomáš - Jarkovský, Jiří - Šanca, Ondřej - Koziar Vasakova, Martina - Dlouhy, Pavel - Cerny, Vladimir - Štourač, Petr - Válek, Vlastimil - Dušek, Ladislav
PY  - 2024
TI  - Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic
JF  - OPEN FORUM INFECTIOUS DISEASES
VL  - 11
IS  - 12
SP  - 1-10
EP  - 1-10
PB  - OXFORD UNIV PRESS INC
SN  - 2328-8957
KW  - 30-day all-cause mortality
KW  - COVID-19
KW  - COVID-19-related mortality
KW  - molnupiravir
KW  - SARS-CoV-2 infection
UR  - https://academic.oup.com/ofid/article/11/12/ofae685/7904736?login=true
N2  - lt; .001). The effect of molnupiravir was highly significant regardless of sex, Deyo-Charlson Comorbidity Index score, hospitalization status, COVID-19 vaccination status, and patients older than age 65 years. Conclusions. In this cohort study, early initiation of molnupiravir was associated with a significant reduction in 30-day all-cause and COVID-19-related mortality in adult SARS-CoV-2 positive patients.
ER  -

PAVLÍK, Tomáš, Jiří JARKOVSKÝ, Ondřej ŠANCA, Martina KOZIAR VASAKOVA, Pavel DLOUHY, Vladimir CERNY, Petr ŠTOURAČ, Vlastimil VÁLEK and Ladislav DUŠEK. Real Clinical Effectiveness of Molnupiravir Against 30-day Mortality Among 74 541 SARS-CoV-2-Positive Patients: A Nationwide Cohort Study From the Czech Republic. \textit{OPEN FORUM INFECTIOUS DISEASES}. CARY: OXFORD UNIV PRESS INC, 2024, vol.~11, No~12, p.~1-10. ISSN~2328-8957. Available from: https://dx.doi.org/10.1093/ofid/ofae685.